Updating the probability of study success for combination therapies using related combination study data

被引:1
|
作者
Graham, Emily [1 ,5 ]
Harbron, Chris [2 ]
Jaki, Thomas [3 ,4 ]
机构
[1] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster, England
[2] Roche Pharmaceut, Welwyn Garden City, England
[3] Univ Regensburg, Regensburg, Germany
[4] Univ Cambridge, MRC Biostat Unit, Cambridge, England
[5] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster LA1 4YF, England
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
Combination therapies; clinical trials; probability of success; Bayesian; assurance; CLINICAL-TRIALS; PHASE-II; TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; POWER; END;
D O I
10.1177/09622802231151218
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Combination therapies are becoming increasingly used in a range of therapeutic areas such as oncology and infectious diseases, providing potential benefits such as minimising drug resistance and toxicity. Sets of combination studies may be related, for example, if they have at least one treatment in common and are used in the same indication. In this setting, value can be gained by sharing information between related combination studies. We present a framework that allows the study success probabilities of a set of related combination therapies to be updated based on the outcome of a single combination study. This allows us to incorporate both direct and indirect data on a combination therapy in the decision-making process for future studies. We also provide a robustification that accounts for the fact that the prior assumptions on the correlation structure of the set of combination therapies may be incorrect. We show how this framework can be used in practice and highlight the use of the study success probabilities in the planning of clinical studies.
引用
收藏
页码:712 / 731
页数:20
相关论文
共 50 条
  • [41] Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting 111In-Trastuzumab for Potential Combination Therapies
    Li, Huizi Keiko
    Morokoshi, Yukie
    Daino, Kazuhiro
    Furukawa, Takako
    Kamada, Tadashi
    Saga, Tsuneo
    Hasegawa, Sumitaka
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2015, 30 (08) : 349 - 358
  • [42] Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
    Sato N.
    Sano M.
    Tabei T.
    Asaga T.
    Ando J.
    Fujii H.
    Yamamoto N.
    Kurosumi M.
    Inoue K.
    Kimura M.
    Breast Cancer, 2006, 13 (2) : 166 - 171
  • [43] Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
    Shin, Dong-Yeop
    Kim, Seok Jin
    Yoon, Dok Hyun
    Park, Yong
    Kong, Jee Hyun
    Kim, Jeong-A
    Kim, Byung-Su
    Kim, Hyo Jung
    Won, Jong-Ho
    Park, Sung-Kyu
    Kim, Won Seog
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 865 - 873
  • [44] Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
    Musa, Fernanda
    Pothuri, Bhavana
    Blank, Stephanie V.
    Ling, Huichung T.
    Speyer, James L.
    Curtin, John
    Boyd, Leslie
    Li, Xiaochun
    Goldberg, Judith D.
    Muggia, Franco
    Tiersten, Amy
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 279 - 284
  • [45] Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer
    Rischin, Danny
    Narayan, Kailash
    Oza, Amit M.
    Mileshkin, Linda
    Bernshaw, David
    Choi, Jimin
    Hicks, Rodney
    McClure, Bev
    Fyles, Anthony
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (05) : 827 - 833
  • [46] Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma
    Ishizaki, Morihiko
    Kaibori, Masaki
    Matsui, Kosuke
    Ikeda, Hiroki
    Yoshida, Katsunori
    Okazaki, Kazuichi
    Kariya, Syuji
    Tanigawa, Noboru
    Nakatake, Richi
    Matsushima, Hideyuki
    Sakaguchi, Tatsuma
    Kon, Masanori
    CANCER INVESTIGATION, 2017, 35 (04) : 271 - 276
  • [47] Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
    Monge, Cecilia
    Xie, Changqing
    Myojin, Yuta
    Coffman, Kelley
    Hrones, Donna Mabry
    Wang, Sophie
    Hernandez, Jonathan M.
    Wood, Bradford J.
    Levy, Elliot B.
    Juburi, Israa
    Hewitt, Stephen M.
    Kleiner, David E.
    Steinberg, Seth M.
    Figg, William D.
    Redd, Bernadette
    Homan, Philip
    Cam, Maggie
    Ruf, Benjamin
    Duffy, Austin G.
    Greten, Tim F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [48] Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma
    Mody, Rajen
    Zhao, Lili
    Yanik, Gregory Anthony
    Opipari, Valerie
    PEDIATRIC BLOOD & CANCER, 2017, 64 (11)
  • [49] Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
    Fujimoto-Ouchi, Kaori
    Sekiguchi, Fumiko
    Yamamoto, Kaname
    Shirane, Masatoshi
    Yamashita, Yoriko
    Mori, Kazushige
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 269 - 276
  • [50] Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer
    Huinink, WWT
    vanWarmerdam, LJC
    Helmerhorst, TJ
    Schaefers, MCW
    Beijnen, JH
    Rodenhuis, S
    ANNALS OF ONCOLOGY, 1997, 8 (04) : 351 - 354